<qa>  What is the name of the antibody, protein, or biological therapy not specifically approved by the F10. Subject has received infliximab; adalimumab; or other antibody, protein, or biological therapy not specifically approved by the United States Food and Drug Administration FDA for Crohns disease for 90 days d prior to enrollment in study. 